NAPHCON-A
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NAPHCON-A (NAPHCON-A).
Naphcon-A combines naphazoline, an alpha-adrenergic receptor agonist, and pheniramine, a histamine H1-receptor antagonist. Naphazoline constricts conjunctival blood vessels via alpha-adrenergic stimulation, reducing redness and edema. Pheniramine blocks histamine effects, alleviating itching and allergic reactions.
| Metabolism | Naphazoline: primarily metabolized in the liver by oxidative deamination and conjugation. Pheniramine: metabolized in the liver via hydroxylation and conjugation, involving CYP450 enzymes. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; naphazoline <10% unchanged, antazoline ~30% unchanged. Biliary/fecal elimination negligible. |
| Half-life | Naphazoline: ~2-3 hours; antazoline: ~3-4 hours. Clinical context: ocular administration, systemic absorption minimal. |
| Protein binding | Naphazoline: ~20-30% bound to plasma proteins; antazoline: ~10-20% bound. |
| Volume of Distribution | Naphazoline: ~1.5-2.0 L/kg (extensive tissue distribution); antazoline: ~1.0-1.5 L/kg. |
| Bioavailability | Ocular: low systemic bioavailability due to local administration and vasoconstriction limiting absorption; <5% of dose reaches systemic circulation. |
| Onset of Action | Ocular: within minutes (vasoconstriction and antihistamine effect). |
| Duration of Action | Ocular: 2-4 hours for decongestant effect; antihistamine effect may last up to 6 hours. |
1-2 drops instilled into the conjunctival sac every 3-4 hours as needed, not to exceed 4 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children ≥6 years: 1 drop every 3-4 hours as needed; safety and efficacy in children <6 years not established. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased sensitivity to anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NAPHCON-A (NAPHCON-A).
| Breastfeeding | Systemic absorption after ocular use is low; M/P ratio unknown. Naphazoline and pheniramine likely excreted in milk in small amounts. Caution in nursing infants, especially those with cardiovascular or neurological conditions. Use only if clearly needed. |
| Teratogenic Risk | NAPHCON-A (naphazoline/pheniramine) ophthalmic: Inadequate human data; animal studies not available. Naphazoline is an alpha agonist; systemic exposure minimal with ocular use. Pheniramine is an H1-antihistamine; no evidence of teratogenicity in animal studies. Risk cannot be excluded. Avoid first trimester unless clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component, narrow-angle glaucoma, children <6 years (safety not established), patients receiving MAO inhibitors (risk of hypertensive crisis).
| Precautions | Do not use if you have narrow-angle glaucoma. Overuse may cause rebound hyperemia and conjunctivitis medicamentosa. Use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, or diabetes. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for ophthalmic use. Monitor for maternal ocular adverse effects (e.g., increased intraocular pressure, systemic effects like hypertension or tachycardia). No fetal monitoring needed due to minimal systemic absorption. |
| Fertility Effects | No known effects on fertility from ocular use. Systemic effects unlikely. No data available. |